Skip Navigation LinksHome > Current Issue > New agents for bacillus Calmette–Guérin-refractory nonmuscle...
Text sizing:
A
A
A
Current Opinion in Urology:
doi: 10.1097/MOU.0000000000000088
HIGH RISK NONMUSCLE INVASIVE BLADDER CANCER: Edited by Shahrokh F. Shariat

New agents for bacillus Calmette–Guérin-refractory nonmuscle invasive bladder cancer

Ahn, Jennifer J.a; Ghandour, Rashed A.a; McKiernan, James M.b,c

Collapse Box

Abstract

Purpose of review: Radical cystectomy is the standard of care for patients who fail intravesical bacillus Calmette–Guérin (BCG) for nonmuscle invasive bladder cancer (NMIBC). For patients unwilling or unable to undergo cystectomy, numerous local therapies exist, although few are approved by the Food and Drug Administration. This review describes available therapies for this challenging clinical entity.

Recent findings: Combination intravesical chemotherapy, targeted therapy, and drug delivery enhancement have all been under recent investigation and are promising, although none has proven superior as of yet.

Summary: While BCG is standard treatment for intermediate and high-risk NMIBC, many patients fail therapy with recurrence or progression. Early cystectomy is the standard of care for BCG failure; however, many patients are unwilling or unable to undergo cystectomy. Multiple intravesical therapies have been used in this BCG failure population with moderate success, and, recently, technologies to improve drug delivery or create novel drugs have also been applied. Comparing efficacy of these therapies remain challenging as study cohorts are heterogeneous and study designs are variable. However, there are an increasing number of novel treatment options that can be offered to patients faced with recurrent NMIBC after BCG who seek bladder-sparing therapy.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.